4D Molecular Therapeutics (NASDAQ:FDMT) Given "Outperform" Rating at Royal Bank Of Canada

Key Points

• 4D Molecular Therapeutics' stock received an "outperform" rating from Royal Bank of Canada with a target price of $26.00, indicating a potential upside of 137.99% from its previous close.
• The company reported negative earnings per share of ($0.98), missing the consensus estimates, with a significant negative net margin of 594,375.81%.
• Institutional investors hold 99.27% of the company's stock, reflecting strong backing from hedge funds and other institutional players.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "outperform" rating reissued by investment analysts at Royal Bank Of Canada in a report issued on Tuesday, MarketBeat Ratings reports. They currently have a $26.00 target price on the stock. Royal Bank Of Canada's price target points to a potential upside of 137.99% from the stock's previous close.

A number of other equities analysts also recently issued reports on FDMT. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Chardan Capital restated a "buy" rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Finally, Roth Capital cut their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $29.50.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock traded down $0.35 during mid-day trading on Tuesday, hitting $10.93. The company's stock had a trading volume of 171,741 shares, compared to its average volume of 836,887. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $11.65. The company has a market cap of $510.20 million, a PE ratio of -3.09 and a beta of 2.93. The company's fifty day simple moving average is $7.68 and its 200-day simple moving average is $5.22.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. On average, equities analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new position in shares of 4D Molecular Therapeutics in the first quarter worth $39,000. Y Intercept Hong Kong Ltd bought a new position in shares of 4D Molecular Therapeutics in the first quarter worth $41,000. Los Angeles Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the second quarter worth $42,000. Quadrature Capital Ltd bought a new position in shares of 4D Molecular Therapeutics in the second quarter worth $42,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock worth $43,000 after purchasing an additional 2,674 shares during the period. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.